Press / Investor Contact:
Director, Investor/Public Relations
Cardium Therapeutics, Inc.
CARDIUM REGAINS LISTING COMPLIANCE WITH NYSE AMEX
SAN DIEGO, CA January 6,
2012 Cardium Therapeutics (NYSE Amex: CXM) today reported that it had received notice from NYSE Regulation that the Company is now considered to have regained compliance with the listing requirements of the NYSE Amex LLC (formerly the
American Stock Exchange).
In the communication from its listing exchange, Cardium was informed that based upon a review of information
provided by the Company and publicly available information, including the Companys Form 8-K filed on January 3, 2012, the Company has resolved the continued listing deficiencies referenced in the NYSE Amex LLCs letter dated
November 26, 2010, as previously reported. In addition, the Exchange also indicated that as with the case for all listed issuers, the Companys continued listing eligibility will continue to be assessed on an ongoing basis and that the
Company is subject to the provisions of Section 1009(h) of the NYSE Amex Company Guide, which may be accessed at www.nyse.com/regulation.
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses
with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardiums current medical opportunities portfolio, which is focused on health sciences
and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Companys in-house MedPodium Health Sciences healthy lifestyle product platform. The Companys lead commercial product Excellagen topical gel
for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardiums lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its
capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first
asset monetization from the Companys biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to
differ materially from stated expectations. For example, there can be no assurance that the company can continue to maintain levels of stockholders equity in excess of the exchanges listing requirements or otherwise achieve and maintain
compliance with all of the requirements of its listing exchange or that its shares can continue to be listed on national exchange; that we can attract suitable commercialization partners for our products or that such partners will successfully
commercialize our products; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one
clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that clinical studies and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory
clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a
broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in
our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such
trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and
critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to
these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2012 Cardium
Therapeutics, Inc. All rights reserved.
Cardium Therapeutics®, Generx®, Cardionovo,
Tissue Repair, Gene Activated Matrix, GAM, Excellagen, Excellarate, Osteorate, MedPodium, Appexium, Linée, Alena, Cerex, and Nutra-Apps, Neo-Energy, and Neo-Carb
Bloc are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.
(Any other trademarks belong to their